A randomized, single-blind, substitution study of oros methylphenidate (concerta) in ADHD adults receiving immediate release methylphenidate

Thomas J. Spencer; Eric Mick; Craig B.H. Surman; Paul Hammerness; Robert Doyle; Megan Aleardi; Meghan Kotarski; Courtney G. Williams; Joseph Biederman

doi:10.1177/1087054710367880

A randomized, single-blind, substitution study of oros methylphenidate (concerta) in ADHD adults receiving immediate release methylphenidate

Thomas J. Spencer, Eric Mick, Craig B.H. Surman, Paul Hammerness, Robert Doyle, Megan Aleardi, Meghan Kotarski, Courtney G. Williams, Joseph Biederman

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Objective: The main aim of this study was to examine the efficacy, tolerability, and compliance of an extended-release formulation of methylphenidate (OROS-MPH) in adults with ADHD receiving immediate-release methylphenidate (IR-MPH). Method: Participants were outpatient adults with ADHD who were stable on IR-MPH-administered TID. Participants were randomized (4:1) to equipotent doses of OROS-MPH or to continue IR-MPH and were assessed weekly for 6 weeks with the Adult ADHD Investigator System Symptom Report Scale (AISRS). Results: Randomization of 53 IR-MPH responders to IR- or OROS-MPH had no effect on AISRS score at endpoint (11.2 ± 6.9 vs. 10.7 ± 5.1,p =.8). Participants stabilized on IR-MPH and switched to OROS-MPH remained satisfied over 71% of the time. However, the IR-MPH group missed more doses (7.3 ± 6.8 vs. 3.3 ±4.2,p =.02) than the OROS-MPH group. Conclusion: Findings showed that adults with ADHD can be successfully switched from an effective regimen of IR-MPH TID to once-daily OROS-MPH. Results also demonstrated better compliance with OROS-MPH than with IR-MPH treatment. (J. of Att. Dis. 2011; 15(4) 286-294)

Original language	English
Pages (from-to)	286-294
Number of pages	9
Journal	Journal of Attention Disorders
Volume	15
Issue number	4
DOIs	https://doi.org/10.1177/1087054710367880
State	Published - May 2011
Externally published	Yes

Keywords

ADHD
adult
clinical trial
methylphenidate

Access to Document

10.1177/1087054710367880

Cite this

@article{086886fad1324aa3b6a454e4b4ea6b3e,

title = "A randomized, single-blind, substitution study of oros methylphenidate (concerta) in ADHD adults receiving immediate release methylphenidate",

abstract = "Objective: The main aim of this study was to examine the efficacy, tolerability, and compliance of an extended-release formulation of methylphenidate (OROS-MPH) in adults with ADHD receiving immediate-release methylphenidate (IR-MPH). Method: Participants were outpatient adults with ADHD who were stable on IR-MPH-administered TID. Participants were randomized (4:1) to equipotent doses of OROS-MPH or to continue IR-MPH and were assessed weekly for 6 weeks with the Adult ADHD Investigator System Symptom Report Scale (AISRS). Results: Randomization of 53 IR-MPH responders to IR- or OROS-MPH had no effect on AISRS score at endpoint (11.2 ± 6.9 vs. 10.7 ± 5.1,p =.8). Participants stabilized on IR-MPH and switched to OROS-MPH remained satisfied over 71\% of the time. However, the IR-MPH group missed more doses (7.3 ± 6.8 vs. 3.3 ±4.2,p =.02) than the OROS-MPH group. Conclusion: Findings showed that adults with ADHD can be successfully switched from an effective regimen of IR-MPH TID to once-daily OROS-MPH. Results also demonstrated better compliance with OROS-MPH than with IR-MPH treatment. (J. of Att. Dis. 2011; 15(4) 286-294)",

keywords = "ADHD, adult, clinical trial, methylphenidate",

author = "Spencer, \{Thomas J.\} and Eric Mick and Surman, \{Craig B.H.\} and Paul Hammerness and Robert Doyle and Megan Aleardi and Meghan Kotarski and Williams, \{Courtney G.\} and Joseph Biederman",

year = "2011",

month = may,

doi = "10.1177/1087054710367880",

language = "English",

volume = "15",

pages = "286--294",

journal = "Journal of Attention Disorders",

issn = "1087-0547",

publisher = "SAGE Publications Inc.",

number = "4",

}

TY - JOUR

T1 - A randomized, single-blind, substitution study of oros methylphenidate (concerta) in ADHD adults receiving immediate release methylphenidate

AU - Spencer, Thomas J.

AU - Mick, Eric

AU - Surman, Craig B.H.

AU - Hammerness, Paul

AU - Doyle, Robert

AU - Aleardi, Megan

AU - Kotarski, Meghan

AU - Williams, Courtney G.

AU - Biederman, Joseph

PY - 2011/5

Y1 - 2011/5

N2 - Objective: The main aim of this study was to examine the efficacy, tolerability, and compliance of an extended-release formulation of methylphenidate (OROS-MPH) in adults with ADHD receiving immediate-release methylphenidate (IR-MPH). Method: Participants were outpatient adults with ADHD who were stable on IR-MPH-administered TID. Participants were randomized (4:1) to equipotent doses of OROS-MPH or to continue IR-MPH and were assessed weekly for 6 weeks with the Adult ADHD Investigator System Symptom Report Scale (AISRS). Results: Randomization of 53 IR-MPH responders to IR- or OROS-MPH had no effect on AISRS score at endpoint (11.2 ± 6.9 vs. 10.7 ± 5.1,p =.8). Participants stabilized on IR-MPH and switched to OROS-MPH remained satisfied over 71% of the time. However, the IR-MPH group missed more doses (7.3 ± 6.8 vs. 3.3 ±4.2,p =.02) than the OROS-MPH group. Conclusion: Findings showed that adults with ADHD can be successfully switched from an effective regimen of IR-MPH TID to once-daily OROS-MPH. Results also demonstrated better compliance with OROS-MPH than with IR-MPH treatment. (J. of Att. Dis. 2011; 15(4) 286-294)

AB - Objective: The main aim of this study was to examine the efficacy, tolerability, and compliance of an extended-release formulation of methylphenidate (OROS-MPH) in adults with ADHD receiving immediate-release methylphenidate (IR-MPH). Method: Participants were outpatient adults with ADHD who were stable on IR-MPH-administered TID. Participants were randomized (4:1) to equipotent doses of OROS-MPH or to continue IR-MPH and were assessed weekly for 6 weeks with the Adult ADHD Investigator System Symptom Report Scale (AISRS). Results: Randomization of 53 IR-MPH responders to IR- or OROS-MPH had no effect on AISRS score at endpoint (11.2 ± 6.9 vs. 10.7 ± 5.1,p =.8). Participants stabilized on IR-MPH and switched to OROS-MPH remained satisfied over 71% of the time. However, the IR-MPH group missed more doses (7.3 ± 6.8 vs. 3.3 ±4.2,p =.02) than the OROS-MPH group. Conclusion: Findings showed that adults with ADHD can be successfully switched from an effective regimen of IR-MPH TID to once-daily OROS-MPH. Results also demonstrated better compliance with OROS-MPH than with IR-MPH treatment. (J. of Att. Dis. 2011; 15(4) 286-294)

KW - ADHD

KW - adult

KW - clinical trial

KW - methylphenidate

UR - https://www.scopus.com/pages/publications/79953726757

U2 - 10.1177/1087054710367880

DO - 10.1177/1087054710367880

M3 - Article

C2 - 20495161

AN - SCOPUS:79953726757

SN - 1087-0547

VL - 15

SP - 286

EP - 294

JO - Journal of Attention Disorders

JF - Journal of Attention Disorders

IS - 4

ER -

A randomized, single-blind, substitution study of oros methylphenidate (concerta) in ADHD adults receiving immediate release methylphenidate

Abstract

Keywords

Access to Document

Fingerprint

Cite this